<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Mild parenchymal lung disease is still lung disease

descriptionPublicationkeyboard_double_arrow_right Article 01 Nov 2020Publisher:European Respiratory Society (ERS)Journal:European Respiratory Journal, volume 56, page 2,003,542 (issn: 0903-1936, eissn: 1399-3003,

Authors: Joan Albert Barberà; Laurent Godinas; Sergio Harari; David Montani; David Montani;

doi: 10.1183/13993003.03542-2020

pmid: 33243773

Mild parenchymal lung disease is still lung disease

- Summary
- Subjects
- Metrics

Abstract

PAH patients with mild parenchymal disease/low DLCO should be considered as group 3 patients with pulmonary vascular phenotypehttps://bit.ly/33awS0J

Related Organizations

University of Milan
Italy
Inserm
France
University of Paris-Saclay
France
Assistance Publique -Hopitaux De Paris
France
Bicêtre Hospital
France

View all View all

Keywords

[SDV] Life Sciences [q-bio], Lung Diseases, Humans, Familial Primary Pulmonary Hypertension, Lung

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	7
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%